Royce & Associates LP Reduces Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Royce & Associates LP decreased its position in OraSure Technologies, Inc. (NASDAQ:OSUR) by 24.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,372 shares of the medical instruments supplier’s stock after selling 27,512 shares during the period. Royce & Associates LP’s holdings in OraSure Technologies were worth $356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in OSUR. Sei Investments Co. increased its holdings in OraSure Technologies by 314.0% in the 1st quarter. Sei Investments Co. now owns 170,748 shares of the medical instruments supplier’s stock worth $1,050,000 after buying an additional 129,509 shares during the period. Russell Investments Group Ltd. boosted its holdings in OraSure Technologies by 1,017.1% in the first quarter. Russell Investments Group Ltd. now owns 178,372 shares of the medical instruments supplier’s stock valued at $1,097,000 after purchasing an additional 162,404 shares during the last quarter. Acadian Asset Management LLC grew its position in OraSure Technologies by 38.1% during the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock worth $9,349,000 after purchasing an additional 605,324 shares during the period. Deerfield Management Company L.P. Series C raised its stake in shares of OraSure Technologies by 428.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 152,003 shares of the medical instruments supplier’s stock valued at $648,000 after buying an additional 123,248 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of OraSure Technologies by 74.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 163,542 shares of the medical instruments supplier’s stock valued at $697,000 after buying an additional 69,625 shares during the period. Institutional investors and hedge funds own 93.50% of the company’s stock.

OraSure Technologies Stock Down 1.3 %

OSUR opened at $3.81 on Thursday. The firm’s fifty day simple moving average is $4.17 and its two-hundred day simple moving average is $4.37. OraSure Technologies, Inc. has a 52-week low of $3.72 and a 52-week high of $8.45. The company has a market cap of $284.19 million, a price-to-earnings ratio of 25.73 and a beta of 0.05.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%. The firm had revenue of $39.92 million for the quarter, compared to analyst estimates of $38.97 million. During the same period last year, the company posted $0.27 EPS. OraSure Technologies’s quarterly revenue was down 55.2% compared to the same quarter last year. On average, research analysts forecast that OraSure Technologies, Inc. will post -0.09 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Evercore ISI upped their price objective on OraSure Technologies from $4.50 to $5.00 and gave the stock an “in-line” rating in a research report on Wednesday, August 7th. StockNews.com upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, October 4th.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.